A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination With Methotrexate Therapy, in Japanese Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate
Phase of Trial: Phase I/II
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs Folic acid (Primary) ; Methotrexate (Primary) ; Otilimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.